We here describe a novel CD4 T cell adoptive transfer model of severe experimental autoimmune encephalomyelitis in (C57BL6xB10.PL)F1 mice. This FI cross developed severe disease characterized by extensive parenchymal spinal cord and brain periventricular white matter infiltrates. In contrast, B10.PL mice developed mild disease characterized by meningeal predominant infiltrates. As determined by cDNA microarray and quantitative real time PCR expression analysis, histologic and flow cytometry analysis of inflammatory infiltrates, and attenuation of disease in class I-deficient and CD8-depleted F1 mice; this severe disease phenotype appears to be regulated by CNS infiltration of CD8 T lymphocytes early in the disease course.
Introduction
Multiple sclerosis (MS) and its animal model, experimental autoimmune encephalomyelitis (EAE), represent a heterogeneous group of demyelinating, inflammatory diseases of the CNS both clinically and pathologically (Keegan and Noseworthy, 2002; Zamvil and Steinman, 1990) . In MS, there are at least four pathologic subtypes of disease (Lucchinetti et al., 2000) , whereas in EAE a multitude of potential phenotypes exist dependent on the species, mode of induction, genetic background, and antigen specificity (Gold et al., 2006) . How inflammation is initiated in these clinical states remains unclear, but appears to be crucial to determining the disease phenotype.
The most common clinical presentation of MS is relapsing, remitting disease where patients experience exacerbations separated in space and time, usually with near complete resolution of symptoms between attacks. After 10 to 15 years from the time of diagnosis, approximately half of patients will go on to develop secondary progressive disease with incomplete recovery and usually accompanied by insidious progression of disease between exacerbations (Weinshenker, 1995) . Approximately 10% of patients have a primary progressive course from disease onset (Thompson et al., 1997) . However, even among patients within these three categories, substantial heterogeneity exists in the clinical course. For example, a subset of newly diagnosed patients have an early, aggressive clinical course that is only partially responsive to currently available immunotherapies (Weinshenker et al., 1989; Cepok et al., 2001) . Even with aggressive immunosuppression, these individuals accumulate profound long term disability and represent the greatest therapeutic challenge within the MS patient population.
One of the goals in EAE disease model development is to replicate these phenotypic differences. Classical EAE induced by active immunization with myelin antigen and adjuvant or by adoptive transfer of myelin-specific CD4 Th1 T lymphocytes results in an ascending myelitis associated with meningeal inflammatory infiltrates (Zamvil and Steinman, 1990; Gold et al., 2006) . From a clinical perspective, these lesions are more similar to non-vasculitic autoimmune meningo-encephalitides seen in patients with acute disseminated encephalomyelitis, connective tissue disease or Hashimoto's encephalitis than they
